SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
PMA Number: P100021 · 2026-05-12
Device Summary
Frequently Asked Questions
What is SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT?
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT is a medical device that received FDA Premarket Approval (PMA) on 2026-05-12. It is manufactured by Medtronic Vascular. The PMA number is P100021.
When did SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT receive FDA PMA approval?
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT received FDA PMA approval on 2026-05-12, under approval number P100021.
What company makes SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT?
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT is manufactured by Medtronic Vascular.
What is the difference between PMA and 510(k)?
PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to provide clinical data proving safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.
What is the FDA product code for SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT?
The FDA product code for SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT is MIH.
What FDA device class is SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT?
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT is classified as Class III by the FDA.
Related PubMed Literature
Other Devices by Medtronic Vascular
Related Devices (Code: MIH)
Official Source
View on FDA Database →Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.